

Drugs with ACB Score of 1

Generic Name	Brand Name
Alimemazine	Theralen™
Alverine	Spasmonal™
Alprazolam	Xanax™
Aripiprazole	Abilify™
Asenapine	Saphris™
Atenolol	Tenormin™
Bupropion	Wellbutrin™, Zyban™
Captopril	Capoten™
Cetirizine	Zyrtec™
Chlorthalidone	Diuril™, Hygroton™
Cimetidine	Tagamet™
Clidinium	Librax™
Clorazepate	Tranxene™
Codeine	Contin™
Colchicine	Colcrys™
Desloratadine	Clarinet™
Diazepam	Valium™
Digoxin	Lanoxin™
Dipyridamole	Persantine™
Disopyramide	Norpace™
Fentanyl	Duragesic™, Actiq™
Furosemide	Lasix™
Fluvoxamine	Luvox™
Haloperidol	Haldol™
Hydralazine	Apresoline™
Hydrocortisone	Cortef™, Cortaid™
Iloperidone	Fanapt™
Isosorbide	Isordil™, Ismo™
Levocetirizine	Xyzal™
Loperamide	Immodium™, others
Loratadine	Claritin™
Metoprolol	Lopressor™, Toprol™
Morphine	MS Contin™, Avinza™
Nifedipine	Procardia™, Adalat™
Paliperidone	Invega™
Prednisone	Deltasone™, Sterapred™
Quinidine	Quinaglute™
Ranitidine	Zantac™
Risperidone	Risperdal™
Theophylline	Theodur™, Uniphyll™
Trazodone	Desyrel™
Triamterene	Dyrenium™
Venlafaxine	Effexor™
Warfarin	Coumadin™

Drugs with ACB Score of 2

Generic Name	Brand Name
Amantadine	Symmetrel™
Belladonna	Multiple
Carbamazepine	Tegretol™
Cyclobenzaprine	Flexeril™
Cyproheptadine	Periactin™
Loxapine	Loxitane™
Meperidine	Demerol™
Methotrimeprazine	Levoprome™
Molindone	Moban™
Nefopam	Nefogesic™
Oxcarbazepine	Trileptal™
Pimozide	Orap™

Drugs with ACB Score of 3

Generic Name	Brand Name
Amitriptyline	Elavil™
Amoxapine	Asendin™
Atropine	Sal-Tropine™
Benzotropine	Cogentin™
Brompheniramine	Dimetapp™
Carbinoxamine	Histex™, Carbihist™
Chlorpheniramine	Chlor-Trimeton™
Chlorpromazine	Thorazine™
Clemastine	Tavist™
Clomipramine	Anafranil™
Clozapine	Clozaril™
Darifenacin	Enablex™
Desipramine	Norpramin™
Dicyclomine	Bentyl™
Dimenhydrinate	Dramamine™, others
Diphenhydramine	Benadryl™, others
Doxepin	Sinequan™
Doxylamine	Unisom™, others
Fesoterodine	Toviaz™
Flavoxate	Urispas™
Hydroxyzine	Atarax™, Vistaril™
Hyoscyamine	Anaspaz™, Levsin™
Imipramine	Tofranil™
Meclizine	Antivert™
Methocarbamol	Robaxin™
Nortriptyline	Pamelor™
Olanzapine	Zyprexa™
Orphenadrine	Norflex™
Oxybutynin	Ditropan™
Paroxetine	Paxil™
Perphenazine	Trilafon™
Promethazine	Phenergan™
Propantheline	Pro-Banthine™
Propiverine	Detrunorm™
Quetiapine	Seroquel™
Scopolamine	Transderm Scop™
Solifenacin	Vesicare™
Thioridazine	Mellaril™
Tolterodine	Detrol™
Trifluoperazine	Stelazine™
Trihexyphenidyl	Artane™
Trimipramine	Surmontil™
Tropium	Sanctura™

Categorical Scoring:

- Possible anticholinergics include those listed with a score of 1; Definite anticholinergics include those listed with a score of 2 or 3

Numerical Scoring:

- Add the score contributed to each selected medication in each scoring category
- Add the number of possible or definite Anticholinergic medications

Notes:

- Each definite anticholinergic may increase the risk of cognitive impairment by 46% over 6 years. ³
- For each on point increase in the ACB total score, a decline in MMSE score of 0.33 points over 2 years has been suggested. ⁴
- Additionally, each one point increase in the ACB total score has been correlated with a 26% increase in the risk of death. ⁴

Aging Brain Care

www.agingbraincare.org

Medications Reviewed in 2012 Update

Medications Added with Score of 1:

Aripiprazole (Abilify™)
Asenapine (Saphris™)
Cetirizine (Zyrtec™)
Clidinium (Librax™)
Desloratadine (Clarinet™)
Iloperidone (Fanapt™)
Levocetirizine (Xyzal™)
Loratadine (Claritin™)
Paliperidone (Invega™)
Venlafaxine (Effexor™)

Medications Added with Score of 2:

Nefopam (Nefogestic™)

Medications Added with Score of 3:

Doxylamine (Unisom™, others)
Fesoterodine (Toviaz™)
Propiverine (Detrunorm™)
Solifenacin (Vesicare™)
Tropium (Sanctura™)

Medications Reviewed But NOT Added:

Fexofenadine (Allegra™)
Gabapentin (Neurontin™)
Topiramate (Topamax™)
Levetiracetam (Keppra™)
Tamoxifen (Nolvadex™)
Nizatidine (Axiid™)
Duloxetine (Cymbalta™)

Criteria for Categorization:

Score of 1: Evidence from in vitro data that chemical entity has antagonist activity at muscarinic receptor.

Score of 2: Evidence from literature, prescriber's information, or expert opinion of clinical anticholinergic effect.

Score of 3: Evidence from literature, expert opinion, or prescribers information that medication may cause delirium.

Complete References:

1. Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. *Aging Health*. 2008;4(3):311-320.
2. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. *Clinical Interventions in Aging*. 2009;4(1):225-233.
3. Campbell N, Boustani M, Lane K, et al. Use of anticholinergics and the risk of cognitive impairment in an African-American population. *Neurology*. 2010;75:152-159.
4. Fox C, Richardson K, Maidment I, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. *Journal of the American Geriatric Society*. 2011; 59(8): 1477-1483.
5. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. *Alzheimers Dementia*. 2012; epub ahead of print.

Copyright © 2008, 2012. Regenstrief Institute, Inc. All rights reserved.

Use of the Anti-Cholinergic Burden (ACB) Scale may only be in accordance with the Terms of Use for the ACB Scale which are available at <http://www.agingbraincare.org/tools/abc-anticholinergic-cognitive-burden-scale>.

To request permission for use, contact us at acb@agingbraincare.org.

Aging Brain Care

ANTICHOLINERGIC COGNITIVE BURDEN SCALE

2012 Update

Developed by the Aging Brain Program
of the Indiana University Center for
Aging Research



Regenstrief Institute



THE NEW
WISHARD

ESKENAZI
HEALTH